Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial - Wagemann, Olivia; Liu, Haiyan; Wang, Guoqiao; Shi, Xinyu; Bittner, Tobias; Scelsi, Marzia A; Farlow, Martin R; Clifford, David B; Supnet-Bell, Charlene; Santacruz, Anna M; Aschenbrenner, Andrew J; Hassenstab, Jason J; et al. (Archives of neurology (Chicago), 2024)
Keywords: Adult; Aged; Alzheimer Disease - blood; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - drug therapy; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; Antibodies, Monoclonal, Humanized - administration & dosage; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Biomarkers; Biomarkers - blood; Biomarkers - cerebrospinal fluid; Cerebrospinal fluid; Chitinase; Chitinase-3-Like Protein 1 - blood; Chitinase-3-Like Protein 1 - cerebrospinal fluid; Clinical trials; Correlation analysis; Dosage; Double-Blind Method; Female; Glial fibrillary acidic protein; Humans; Inflammation; Male; Medical imaging; Middle Aged; Myeloid cells; Neurodegeneration; Neurodegenerative diseases; Neurofilament Proteins - blood; Neurofilament Proteins - cerebrospinal fluid; Neurogranin; Neuroimaging; Neuronal-glial interactions; Peptides; Placebos; Plasma; Plasma levels; Positron emission; Positron emission tomography; Proteins